Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Expands By 28.9%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 148,000 shares, an increase of 28.9% from the November 30th total of 114,800 shares. Approximately 3.9% of the shares of the company are sold short. Based on an average daily volume of 207,100 shares, the days-to-cover ratio is currently 0.7 days.

Analysts Set New Price Targets

Several brokerages have commented on VVOS. Alliance Global Partners lowered their price target on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 19th. Ascendiant Capital Markets reaffirmed a “buy” rating and set a $6.60 price objective on shares of Vivos Therapeutics in a report on Wednesday, November 20th.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $4.50 on Monday. The stock has a 50-day simple moving average of $3.57 and a 200 day simple moving average of $2.90. Vivos Therapeutics has a twelve month low of $1.91 and a twelve month high of $12.75. The stock has a market capitalization of $21.76 million, a PE ratio of -0.79 and a beta of 7.67.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.